Ddt: Carcinogenic Potency Database

DDT (CAS 50-29-3)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
liv	liv	hmo liv lun	hmo liv lun	84.7^m	12.8^m,v

Hamsters: Cancer Test Summary

Hamster Target Sites		TD₅₀ (mg/kg/day)
Male	Female	TD₅₀ (mg/kg/day)
no positive	no positive	no positive

Monkeys: Cancer Test Summary

Monkey Target Sites		TD₅₀ (mg/kg/day)
Rhesus	Cynomulgus	Rhesus	Cynomulgus
no positive	no positive	no positive	no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: hmo = hematopoietic system. liv = liver. lun = lung. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD₅₀ values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

DDT: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



DDT   50-29-3
1714 H f nss eat 78w78 2596                          0    26.1mg  52.3mg  105.mg                        Graillot;ejtx,8,353-359;1975
 liv tum        no dre   P=1.    -  51.9mg n.s.s.   0/30    0/30    0/30    0/30
1715 H m nss eat 78w78 2596                          0    23.0mg  46.0mg  92.0mg
 liv tum        no dre   P=1.    -  45.7mg n.s.s.   0/30    0/30    0/30    0/30
1716 H f syg eat 28m28 1179                          0    13.1mg  26.1mg  52.3mg                            Cabral;tumo,68,5-10;1982
 liv tum e      no dre   P=1.       59.9mg n.s.s.   0/39    0/28    0/28    0/40
 tba mix e      639.mg * P<.4    -  154.mg n.s.s.   5/39    3/28    2/28    8/40
1717 H f syg eat 48w88 1400                          0    28.5mg                                         Agthe;pseb,134,113-116;1970
 tba mix e      no dre   P=1.    -  34.8mg n.s.s.   3/6     3/17
1718 H f syg eat 28m28 1556                          0    105.mg                                          Rossi;canr,43,776-781;1983
 adr ade e      345.mg   P<.005  -  152.mg 3.14gm   2/42   10/36
 liv hem e      3.39gm   P<.3    -  551.mg n.s.s.   0/42    1/36
 lun tum e      no dre   P=1.    -  1.03gm n.s.s.   2/42    0/36
 tba mix e      781.mg   P<.5    -  158.mg n.s.s.  13/42   14/36
1719 H m syg eat 28m28 1179                          0    11.5mg  23.0mg  46.0mg                            Cabral;tumo,68,5-10;1982
 liv mix e      311.mg Z P<.03      94.1mg n.s.s.   0/40    0/30    3/31   (0/39)
 tba mix e      145.mg * P<.02   -  68.7mg n.s.s.   3/40    5/30    8/31   11/39
1720 H m syg eat 48w85 1400                          0    26.0mg                                         Agthe;pseb,134,113-116;1970
 tba mix e      113.mg   P<.2    -  34.1mg n.s.s.   0/11    3/30
1721 H m syg eat 28m28 1556                          0    92.0mg                                          Rossi;canr,43,776-781;1983
 liv tum e      no dre   P=1.    -  883.mg n.s.s.   0/31    0/35
 lun tum e      no dre   P=1.    -  883.mg n.s.s.   1/31    0/35
 tba mix e      no dre   P=1.    -  167.mg n.s.s.  15/31   15/35
1722 M f b6c eat 78w92 TR131 :                       0    9.50mg  19.5mg
 --- lym v#     61.2mg * P<.02   -  29.8mg n.s.s.   0/20    3/50    7/50                                                           S
 TBA MXB v      59.2mg * P<.2       22.4mg n.s.s.   2/20    8/50   10/50
 liv MXB v      151.mg * P<.09      52.1mg n.s.s.   0/20    1/50    3/50                                          liv:hpa,hpc,nnd.
 lun MXB v      no dre   P=1.       n.s.s. n.s.s.   0/20    1/50    0/50                                              lun:a/a,a/c.
1723 M f b6c orl 80w80 133                           0    19.3mg                                                Innes;ntis,1968/1969
 liv hpt evx    31.1mg   P<.02      10.7mg n.s.s.   0/16    4/18
 lun mix evx    no dre   P=1.       42.3mg n.s.s.   0/16    0/18
 tba mix evx    24.0mg   P<.009     9.05mg 526.mg   0/16    5/18
1724 M m b6c eat 78w91 TR131 :                       0    2.30mg  4.40mg
 TBA MXB sv     2.04mg \ P<.4    -  .345mg n.s.s.   4/20    6/50   (4/50)
 liv MXB sv     no dre   P=1.       4.67mg n.s.s.   2/20    1/50    1/50                                          liv:hpa,hpc,nnd.
 lun MXB sv     no dre   P=1.       4.67mg n.s.s.   1/20    1/50    0/50                                              lun:a/a,a/c.
1725 M m b6c orl 80w80 133                           0    17.9mg                                                Innes;ntis,1968/1969
 liv hpt evx    8.95mg   P<.0005 +  4.24mg 23.7mg   0/16   10/18
 lun ade evx    127.mg   P<.3       20.7mg n.s.s.   0/16    1/18
 lun car evx    127.mg   P<.3       20.7mg n.s.s.   0/16    1/18
 tba mix evx    7.69mg   P<.0005    3.72mg 19.2mg   0/16   11/18
1726 M f b6a orl 80w80 133                           0    19.3mg
 --- rts evx    19.3mg   P<.003  +  7.78mg 106.mg   0/17    6/18
 liv hpt evx    137.mg   P<.3       22.2mg n.s.s.   0/17    1/18
 lun ade evx    no dre   P=1.       42.3mg n.s.s.   1/17    0/18
 tba mix evx    21.3mg   P<.07      7.42mg n.s.s.   2/17    7/18
1727 M m b6a orl 80w80 133                           0    17.9mg
 liv hpt evx    16.7mg   P<.02   +  6.56mg n.s.s.   1/18    7/18
 lun ade evx    no dre   P=1.       18.5mg n.s.s.   2/18    2/18
 tba mix evx    17.9mg   P<.07      6.21mg n.s.s.   3/18    8/18
1728 M f bal eat 31m31 88                            0    .260mg  2.60mg  32.5mg                      Terracini;ijcn,11,747-764;1973
 liv lct eg     59.5mg * P<.0005 +  37.8mg 101.mg   0/50    0/58    1/50   28/57
 lun ade g      no dre   P=1.    -  238.mg n.s.s.  20/62   20/63   20/61   14/63
 tba mix g      no dre   P=1.       73.1mg n.s.s.  56/62   51/63   48/61   48/63
1729 M f cf1 eat 26m26 89                            0    12.6mg                                         Thorpe;fctx,11,433-442;1973
 liv mix e      5.82mg   P<.0005 +  3.06mg 13.0mg  10/44   26/30
 liv lct e      20.0mg   P<.0005 +  10.2mg 47.1mg   0/44   12/30
 lun tum e      no dre   P=1.    -  40.4mg n.s.s.  27/44    9/30
1730 M f cf1 eat 31m31 90                            0    .260mg  1.30mg  6.50mg  32.5mg                Tomatis;ijcn,10,489-506;1972
 liv hpt eg     43.0mg * P<.0005 +  28.1mg 71.8mg   2/56    3/56    2/59    7/55   31/49
 lun tum eg     121.mg * P<.04   -  47.7mg n.s.s.  13/56   17/56   22/59   23/55   23/49
 ute tum eg     no dre   P=1.    -  334.mg n.s.s.   2/56    8/56    3/59    4/55    2/49
 tba mix eg     106.mg * P<.5       20.1mg n.s.s.  45/56   50/56   52/59   48/55   44/49
1731 M f cf1 eat 26m26 103                           0    6.50mg  13.0mg                                 Walker;fctx,11,415-432;1973
 liv mix e      9.11mg * P<.0005 +  5.53mg 18.6mg   8/47   15/30   24/32
 liv lpb e      76.5mg * P<.007     31.2mg 895.mg   0/47    2/30    4/32
 lun ade e      no dre   P=1.    -  52.1mg n.s.s.  19/47    6/30    7/32
 lun car e      no dre   P=1.    -  48.8mg n.s.s.   3/47    5/30    1/32
1732 M f cf1 eat  7m28 1012                          0    8.13mg                                          Tomatis;zkko,82,25-35;1974
 liv hpt        34.2mg   P<.0005 +  16.7mg 99.9mg   1/90   11/54
 tba tum        no dre   P=1.       13.0mg n.s.s.  77/90   41/54
1733 M f cf1 eat 30w95 1012m                         0    10.3mg
 liv hpt        26.3mg   P<.0005 +  13.2mg 64.3mg   0/72   11/55
 tba tum        17.9mg   P<.4       4.65mg n.s.s.  52/72   44/55
1734 M f cf1 eat 30w65 1012n                         0    15.0mg
 liv hpt        52.2mg   P<.01   +  18.0mg 5.13gm   0/69    4/54
 tba tum        150.mg   P<.9       9.20mg n.s.s.  27/69   22/54
1735 M m cf1 eat 26m26 89                            0    11.7mg                                         Thorpe;fctx,11,433-442;1973
 liv mix e      8.04mg   P<.0005 +  4.17mg 21.3mg  11/45   23/30
 liv lct e      30.3mg   P<.003  +  13.1mg 195.mg   2/45    9/30
 lun tum e      no dre   P=1.    -  29.5mg n.s.s.  27/45   11/30
1736 M m cf1 eat 29m31 90                            0    .240mg  1.20mg  6.00mg  30.0mg                Tomatis;ijcn,10,489-506;1972
 liv hpt e      34.7mg * P<.0005 +  19.4mg 86.6mg  12/55   25/58   28/53   24/53   38/50
 lun tum e      no dre   P=1.    -  151.mg n.s.s.  23/55   38/58   29/53   27/53   19/50
 tba mix e      no dre   P=1.       24.9mg n.s.s.  46/55   53/58   48/53   49/53   44/50
1737 M m cf1 eat 26m26 103                           0    6.00mg  12.0mg                                 Walker;fctx,11,415-432;1973
 liv mix e      15.0mg * P<.0005 +  8.40mg 43.3mg   6/47   12/32   17/32
 liv lpb e      72.6mg * P<.02      29.6mg n.s.s.   0/47    3/32    3/32
 lun ade e      49.3mg * P<.4    -  12.9mg n.s.s.  18/47   13/32   16/32
 lun car e      no dre   P=1.    -  30.6mg n.s.s.   0/47    0/32    0/32
1738 M m cf1 eat  7m28 1012                          0    7.50mg                                          Tomatis;zkko,82,25-35;1974
 liv hpt        12.5mg   P<.002  +  6.40mg 53.1mg  33/98   37/60
 tba tum        no dre   P=1.       8.22mg n.s.s.  83/98   49/60
1739 M m cf1 eat 30w95 1012m                         0    9.47mg
 liv hpt        6.70mg   P<.0005 +  3.86mg 15.9mg  24/83   41/60
 tba tum        4.59mg   P<.02      1.90mg n.s.s.  65/83   56/60
1740 M m cf1 eat 30w65 1012n                         0    13.8mg
 liv hpt        4.55mg   P<.0005 +  2.76mg 9.13mg  12/70   38/60
 tba tum        5.35mg   P<.02      2.39mg n.s.s.  42/70   48/60
1741 M f swi eat 80w80 2176m                         0    13.0mg                             Kashyap;ijcn,19,725-729;1977/pers.comm.
 --- lkm        21.9mg   P<.04   +  8.35mg n.s.s.   2/30    8/30
 liv hpc        50.0mg   P<.04   +  15.1mg n.s.s.   0/30    3/30
 lun ade        73.8mg   P<.3    +  16.3mg n.s.s.   1/30    3/30
 tba mix        10.3mg   P<.006     4.68mg 138.mg   5/30   15/30
1742 M f swi gav 80w80 2176n                         0    7.14mg
 --- lkm        12.0mg   P<.04   +  4.59mg n.s.s.   2/30    8/30
 lun ade        19.5mg   P<.08   +  6.37mg n.s.s.   1/30    5/30
 liv hpc        20.2mg   P<.02   +  6.98mg n.s.s.   0/30    4/30
 tba mix        3.16mg   P<.0005    1.64mg 9.24mg   5/30   20/30
1743 M m swi eat 80w80 2176m                         0    12.0mg
 --- lkm        20.2mg   P<.04   +  7.70mg n.s.s.   2/30    8/30
 lun ade        29.1mg   P<.2    +  8.51mg n.s.s.   4/30    8/30
 liv hpc        44.6mg   P<.2    +  12.5mg n.s.s.   1/30    4/30
 tba mix        5.31mg   P<.003     2.52mg 30.6mg  10/30   22/30
1744 M m swi gav 80w80 2176n                         0    7.14mg
 --- lkm        18.8mg   P<.2       5.87mg n.s.s.   2/30    6/30
 lun ade        23.6mg   P<.4       5.77mg n.s.s.   4/30    7/30
 liv hpc        82.5mg   P<.6       11.3mg n.s.s.   1/30    2/30
 tba mix        10.1mg   P<.2       3.09mg n.s.s.  10/30   15/30
1745 P b cym eat 11y25 2003 :                        0    9.95mg           Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/
                                                                                                      Thorgeirsson&Seiber pers.comm.
 eso ley w      16.6mg   P<.2       2.70mg n.s.s.   0/3     1/2
 liv hpc w      49.8mg   P<.2       8.11mg n.s.s.   0/10    1/5
 pro car w      105.mg   P<.2       17.1mg n.s.s.   0/13    1/10
 ute ley w      271.mg   P<.7       21.0mg n.s.s.   1/25    1/12
 tba mix w      21.4mg   P<.4       3.57mg n.s.s.   4/25    4/12
 tba ben w      60.1mg   P<.6       4.77mg n.s.s.   2/25    2/12
 tba mal w      78.8mg   P<.8       5.33mg n.s.s.   3/15    2/10
1746 P b rhe eat 11y25 2003 :                        0    10.8mg
 ute ley w      no dre   P=1.       7.35mg n.s.s.   6/29    1/5
 tba ben Ww     no dre   P=1.       8.99mg n.s.s.  12/108   1/11
1747 R f osm eat 18m26 TR131 :                       0    7.40mg  15.0mg
 TBA MXB v      no dre   P=1.    -  16.8mg n.s.s.  16/20   38/50   27/50
 liv MXB v      no dre   P=1.       n.s.s. n.s.s.   0/20    0/50    0/50                                          liv:hpa,hpc,nnd.
1748 R f osm eat 27m27 21                            0    10.0mg                                       Deichmann;txap,11,88-103;1967
 liv hpt        256.mg   P<.3    -  41.7mg n.s.s.   0/30    1/30
 tba mix        no dre   P=1.    -  24.3mg n.s.s.  13/30    9/30
1749 R f osm eat 24m24 84a                           0    4.00mg                                        Radomski;txap,7,652-656;1965
 liv mal        no dre   P=1.    -  24.7mg n.s.s.   1/30    0/30
1750 R m osm eat 18m26 TR131 :                       0    8.80mg  18.4mg
 TBA MXB v      no dre   P=1.    -  14.2mg n.s.s.  10/20   29/50   32/50
 liv MXB v      no dre   P=1.       n.s.s. n.s.s.   0/20    0/50    0/50                                          liv:hpa,hpc,nnd.
1751 R m osm eat 27m27 21                            0    8.00mg                                       Deichmann;txap,11,88-103;1967
 liv tum        no dre   P=1.    -  62.6mg n.s.s.   0/30    0/30
 tba mix        no dre   P=1.    -  37.8mg n.s.s.   1/30    1/30
1752 R m osm eat 24m24 84a                           0    3.20mg                                        Radomski;txap,7,652-656;1965
 liv mal        no dre   P=1.    -  19.8mg n.s.s.   0/30    0/30
1753 R b alb eat 60w60 1457                          0    .360mg                                         Cameron;bmjl,2,819-821;1951
 liv tum k      no dre   P=1.    -  .148mg n.s.s.   0/6     0/6
1754 R m f34 eat 17m24 1803                          0    14.0mg                                     Shivapurkar;carc,7,547-550;1986
 liv nnd er     56.2mg   P<.2    -  17.6mg n.s.s.   2/28    6/28
1755 R f por eat 33m33 1178                          0    6.25mg  12.5mg  25.0mg                           Cabral;tumo,68,11-17;1982
 liv lct        140.mg * P<.002  +  74.0mg 552.mg   0/38    2/30    4/30    7/38
 tba mix        no dre   P=1.       47.0mg n.s.s.  32/38   26/30   27/30   27/38
1756 R m por eat 33m33 1178                          0    5.00mg  10.0mg  20.0mg
 liv lct        902.mg * P<.4    -  174.mg n.s.s.   1/38    0/30    1/30    2/38
 tba mix        90.1mg * P<.3       24.5mg n.s.s.  20/38   19/30   18/30   25/38
1757 R f wis eat 34m34 85                            0    25.0mg                                          Rossi;ijcn,19,179-185;1977
 liv hpt ev     57.2mg   P<.0005 +  31.1mg 122.mg   0/32   15/34
 tba mix v      116.mg   P<.4       29.5mg n.s.s.  19/35   23/35
1758 R m wis eat 34m34 85                            0    20.0mg
 liv hpt e      92.6mg   P<.0005 +  43.5mg 272.mg   0/35    9/36
 tba mix        no dre   P=1.       42.6mg n.s.s.  19/36   19/37

Mutagenicity in Salmonella: negative
SMILES Code for DDT: ClC(C(C1=CC=C(C=C1)Cl)C2=CC=C(C=C2)Cl)(Cl)Cl
InChI Code for DDT: InChI=1/C14H9Cl5/c15-11-5-1-9(2-6-11)13(14(17,18)19)10-3-7-12(16)8-4-10/h1-8,13H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for DDT:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007